Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Company Information

Vienna – On 10 April 2017, Semperit AG Holding announced in accordance with Article 17 of the EU Market Abuse Regulation that the long-term earnings outlook for the Sempermed segment (Medical Sector) had to undergo a critical review compared with the previous assessment, which could result in a significant impairment in the Sempermed segment.

Following an in-depth review, the Management Board of Semperit AG Holding has come to the conclusion today that the sustainably achievable production volume at the site in Kamunting, Malaysia, is lower than previously assumed. As a result, an impairment of approximately EUR 26 million has to be recognised in the interim consolidated financial statements as of 30 June 2017. Thus, based on current knowledge, the goodwill of the segment will be completely impaired.

The exact amount of the impairment will be announced with the publication of the half-year financial report 2017 on 17 August 2017.

end of announcement euro adhoc

issuer: Semperit AG Holding Modecenterstrasse 22 A-1030 Wien
phone: +43 1 79 777-210
FAX: +43 1 79 777-602
mail: stefan.marin@semperitgroup.com
WWW: www.semperitgroup.com
ISIN: AT0000785555
indexes: WBI, ATX GP
stockmarkets: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/2918/aom

Rückfragen & Kontakt:

Martina Büchele
Group Communications Manager
Tel.: +43 676 8715 8621

Stefan Marin
Head of Investor Relations
Tel.: +43 676 8715 8210



(C) Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender.